Trending News Today: Trump to Cut $340 Million from the Office of National Drug Control Policy

More than 2 dozen Democratic senators are questioning the legality of newly-proposed Medicaid work requirements, according to ABC News. Last week, the Trump administration rolled out a new policy that would allow states to implement work requirements for Medicaid beneficiaries and approved Kentucky’s request to impose the guidelines. The Democrats’ letter to the acting health secretary was framed similarly to a legal memo preparing for a lawsuit to challenge the new rules on behalf of Medicaid beneficiaries, according to the article.

The CDC has said that this year’s influenza season has been the worst in recent history. This past week alone, 1600 New Yorkers have been hospitalized with the flu, according to The Wall Street Journal. New York Gov Andrew Cuomo said that new cases of the flu increased by 54% within the last week and there were new diagnoses in all counties of the state, according to the article. The state’s health department is advising that all residents receive a vaccine if they haven’t already.

President Donald Trump recently announced plans to slash the budget of the Office of National Drug Control Policy (ONDCP), Politico reported. This plan would redirect a grant from the High Intensity Drug Trafficking Areas to the Department of Justice and redirect a grant from the Drug Free Communities Act to the Department of Health and Human Services. Notably, this proposal would reduce the ONDCP budget by 95% ($340 million), according to the article.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.
There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.